155 related articles for article (PubMed ID: 26982101)
21. Humanized antihuman IL-6 receptor antibody, tocilizumab.
Nishimoto N; Kishimoto T
Handb Exp Pharmacol; 2008; (181):151-60. PubMed ID: 18071945
[TBL] [Abstract][Full Text] [Related]
22. Crystal structures of the pro-inflammatory cytokine interleukin-23 and its complex with a high-affinity neutralizing antibody.
Beyer BM; Ingram R; Ramanathan L; Reichert P; Le HV; Madison V; Orth P
J Mol Biol; 2008 Oct; 382(4):942-55. PubMed ID: 18708069
[TBL] [Abstract][Full Text] [Related]
23. Targeting IL-6 in the treatment of inflammatory and autoimmune diseases.
Ding C; Cicuttini F; Li J; Jones G
Expert Opin Investig Drugs; 2009 Oct; 18(10):1457-66. PubMed ID: 19715447
[TBL] [Abstract][Full Text] [Related]
24. Protective effect of a germline, IL-17-neutralizing antibody in murine models of autoimmune inflammatory disease.
Dallenbach K; Maurer P; Röhn T; Zabel F; Kopf M; Bachmann MF
Eur J Immunol; 2015 Apr; 45(4):1238-47. PubMed ID: 25545966
[TBL] [Abstract][Full Text] [Related]
25. Structural Mimicry of Receptor Interaction by Antagonistic Interleukin-6 (IL-6) Antibodies.
Blanchetot C; De Jonge N; Desmyter A; Ongenae N; Hofman E; Klarenbeek A; Sadi A; Hultberg A; Kretz-Rommel A; Spinelli S; Loris R; Cambillau C; de Haard H
J Biol Chem; 2016 Jun; 291(26):13846-54. PubMed ID: 27129274
[TBL] [Abstract][Full Text] [Related]
26. New therapeutic options in rheumatoid arthritis: a focus on interleukin-6 blockade.
Furfaro N
J Infus Nurs; 2011; 34(2):107-15. PubMed ID: 21399456
[TBL] [Abstract][Full Text] [Related]
27. [Anti-cytokines in the treatment of inflammation].
Mariette X
Rev Prat; 2003 Mar; 53(5):507-11. PubMed ID: 12722608
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic Targeting of CD6 in Autoimmune Diseases: A Review of Cuban Clinical Studies with the Antibodies IOR-T1 and Itolizumab.
Hernández P; Moreno E; Aira LE; Rodríguez PC
Curr Drug Targets; 2016; 17(6):666-77. PubMed ID: 26844560
[TBL] [Abstract][Full Text] [Related]
29. Interleukin-6 in rheumatoid arthritis.
Nishimoto N
Curr Opin Rheumatol; 2006 May; 18(3):277-81. PubMed ID: 16582692
[TBL] [Abstract][Full Text] [Related]
30. Interleukin (IL-6) Immunotherapy.
Tanaka T; Narazaki M; Kishimoto T
Cold Spring Harb Perspect Biol; 2018 Aug; 10(8):. PubMed ID: 28778870
[TBL] [Abstract][Full Text] [Related]
31. Interleukin-6 as a therapeutic target in candidate inflammatory diseases.
Nishimoto N
Clin Pharmacol Ther; 2010 Apr; 87(4):483-7. PubMed ID: 20182422
[TBL] [Abstract][Full Text] [Related]
32. The Th17 pathway as a therapeutic target in rheumatoid arthritis and other autoimmune and inflammatory disorders.
Roeleveld DM; van Nieuwenhuijze AE; van den Berg WB; Koenders MI
BioDrugs; 2013 Oct; 27(5):439-52. PubMed ID: 23620106
[TBL] [Abstract][Full Text] [Related]
33. Interleukin-6 as a key player in systemic inflammation and joint destruction.
Fonseca JE; Santos MJ; Canhão H; Choy E
Autoimmun Rev; 2009 Jun; 8(7):538-42. PubMed ID: 19189867
[TBL] [Abstract][Full Text] [Related]
34. IL-17 and IL-17R: an auspicious therapeutic target for psoriatic disease.
Mitra A; Raychaudhuri SK; Raychaudhuri SP
Actas Dermosifiliogr; 2014 Oct; 105 Suppl 1():21-33. PubMed ID: 25398489
[TBL] [Abstract][Full Text] [Related]
35. ABT-874, a fully human monoclonal anti-IL-12/IL-23 antibody for the potential treatment of autoimmune diseases.
Ding C; Xu J; Li J
Curr Opin Investig Drugs; 2008 May; 9(5):515-22. PubMed ID: 18465662
[TBL] [Abstract][Full Text] [Related]
36. An affibody-adalimumab hybrid blocks combined IL-6 and TNF-triggered serum amyloid A secretion in vivo.
Yu F; Gudmundsdotter L; Akal A; Gunneriusson E; Frejd F; Nygren PÅ
MAbs; 2014; 6(6):1598-607. PubMed ID: 25484067
[TBL] [Abstract][Full Text] [Related]
37. [Treatment of systemic autoimmune and inflammatory diseases with rituximab].
Bussone G; Hachulla E; Sibilia J; Michel M; Godeau B; Guillevin L; Mouthon L
Presse Med; 2009 May; 38(5):808-23. PubMed ID: 19297127
[TBL] [Abstract][Full Text] [Related]
38. Production of a human neutralizing monoclonal antibody and its crystal structure in complex with ectodomain 3 of the interleukin-13 receptor α1.
Redpath NT; Xu Y; Wilson NJ; Fabri LJ; Baca M; Andrews AE; Braley H; Lu P; Ireland C; Ernst RE; Woods A; Forrest G; An Z; Zaller DM; Strohl WR; Luo CS; Czabotar PE; Garrett TP; Hilton DJ; Nash AD; Zhang JG; Nicola NA
Biochem J; 2013 Apr; 451(2):165-75. PubMed ID: 23384096
[TBL] [Abstract][Full Text] [Related]
39. Tocilizumab, a humanized anti-IL-6R antibody, as an emerging therapeutic option for rheumatoid arthritis: molecular and cellular mechanistic insights.
Hashizume M; Tan SL; Takano J; Ohsawa K; Hasada I; Hanasaki A; Ito I; Mihara M; Nishida K
Int Rev Immunol; 2015 May; 34(3):265-79. PubMed ID: 25099958
[TBL] [Abstract][Full Text] [Related]
40. [Recombinant proteins or monoclonal antibodies: comparative properties and interest in rheumatoid arthritis].
Sibilia J
Med Sci (Paris); 2009 Dec; 25(12):1033-8. PubMed ID: 20035675
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
